Tiziana Life Sciences Announces Purchase of Shares by Chief Executive Officer
Rhea-AI Summary
Tiziana Life Sciences (Nasdaq: TLSA) reported that Chief Executive Officer Ivor Elrifi purchased 321,423 common shares on Nasdaq at $1.00 per share, increasing his total holding to 4,793,684 shares. The company focuses on immunomodulation therapies using its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody.
According to Tiziana Life Sciences, 14 patients with non-active secondary progressive multiple sclerosis (na-SPMS) have been dosed in an open-label, intermediate-size Expanded Access Program, with improvement or disease stability observed within six months in all patients. Intranasal foralumab is also being evaluated in a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in na-SPMS. The company states that foralumab is currently the only fully human anti-CD3 mAb in clinical development and has shown a favorable safety profile and clinical response in studies to date.
Positive
- CEO share purchase: Ivor Elrifi bought 321,423 shares at $1.00, bringing his holding to 4,793,684 shares
- Expanded Access data: 14 na-SPMS patients dosed, all showing improvement or disease stability within 6 months
- Phase 2a trial underway for intranasal foralumab in non-active secondary progressive multiple sclerosis
- Only fully human anti-CD3 mAb currently in clinical development, according to Tiziana Life Sciences
Negative
- None.
News Market Reaction – TLSA
In the Aug 6 session, TLSA declined 1.59%, reflecting a mild negative market reaction. Argus tracked a peak move of +3.0% during that session. Argus tracked a trough of -7.7% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. Trading volume was very high at 4.2x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jul 22 | Executive share purchase | Positive | -5.5% | Executive chairman purchased 42,357 shares at $0.99 per share |
| Jun 25 | Phase 2 dosing | Positive | +0.9% | Last patient received first dose in the INFORM-MS Phase 2a trial |
| Jun 15 | Executive share purchase | Positive | +0.9% | Executive chairman purchased 15,000 shares at $1.11 per share |
| May 28 | Healthcare conference | Neutral | -0.7% | Company announced a June 4 corporate presentation at Jefferies conference |
| May 21 | Phase 2 enrollment | Positive | -9.3% | INFORM-MS fully enrolled 48 patients in the Phase 2a trial |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions were mixed, with positive developments producing both gains and declines; the prior executive-chairman purchase diverged with a -5.5% reaction.
Key Terms
anti-cd3 monoclonal antibody medical
expanded access regulatory
double-blind technical
placebo-controlled technical
dose-ranging technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Chief Executive Officer, Ivor Elrifi has increased his holdings with the purchase of 321,423 of the Company’s common shares on NASDAQ at
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
